#160;In addition, the forward-looking statements included in this press release represent Cynosure's views as of the date of this press release. Cynosure anticipates that subsequent events and developments will cause its views to change. However, while Cynosure may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Cynosure's views as of any date subsequent to the date of this press release.
Contact:
Scott Solomon
Vice President
Sharon Merrill Associates, Inc.
Phone: (617) 542-5300
CYNO@investorrelations.comConsolidated Statements of Income (Unaudited)(In thousands, except per share data)Three Months Ended Mar. 31,20112010Revenues$
21,884
$
8,893Cost of revenues 9,803
8,093Gross profit12,081
10,800Operating expensesSelling and marketing
8,756
8,402Research and development
2,240
1,707General and administrative
2,951
3,233Total operating expenses13,947
13,342Loss from operations(1,866)
(2,542)Interest income, net
54
53Other income (expense), net
214
(151)Loss before income taxes(1,598)
(2,640)Income tax provision
296
172Net loss$
(1,894)
$
(2,812)Diluted net loss per share
$
(0.15)
$
(0.22)Diluted weighted average shares outstanding
12,577
12,711Basic net loss per share
$
(0.15)
$
(0.22)Basic weighted average shares outstanding
12,577
12,711Condensed Consolidated Balance Sheet(In thousands)Mar. 31,Dec. 31,20112010(unaudited)Assets:Cash, cash equivalents and short-term marketable securities
$ 81,841$ 86,836Accounts receivable, net
10,39710,621Inventories
21,27118
'/>"/>
SOURCE Cynosure, Inc. Copyright©2010 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 Related biology technology :1.
Cynosure Launches New Workstation and Technology Innovations at American Academy of Dermatology Annual Meeting2.
Cynosure Announces Presentations at Upcoming Investor Conferences3.
Cynosure Reports Second Quarter 2009 Financial Results4.
Cynosure Reports Third Quarter 2009 Financial Results5.
SCOLR Pharma, Inc. Reports Second Quarter 2008 Financial Results6.
AutoImmune Inc. Reports 2008 Second Quarter Financial Results7.
Par Pharmaceutical Reports Second Quarter 2008 Results8.
ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results9.
Pharmos Corporation Reports 2008 Second Quarter Results10.
Halozyme Therapeutics Reports 2008 Second Quarter Financial Results11.
MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments